Biotech News
-
Voyageur Announces Shares for Debt Settlement and Stock Option Repricing
April 17, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the “Company” or “Voyageur”), a Canadian developer of pharmaceutical-grade…
-
Voyageur Announces Non-Brokered Life Offering
March 25, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the “Company” or “Voyageur”), a Canadian developer of pharmaceutical-grade…
-
Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects
March 16, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (the “Company” or “Voyageur”), a…
-
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt
Purity Exceeding Pharmaceutical Grade, 98.8% BaSO4 Moving on to Stage 2 of the Alberta Innovates AICE-Market Access Program …
-
Voyageur Pharmaceuticals Announces Collaboration with Bayer
February 23, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”) a Canadian developer of…
-
DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress
January 13, 2026 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology
January 12, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a Canadian developer…
-
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
December 18, 2025 (Source) — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on…
-
LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million…
-
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion
November 7, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) (the “Company” or “Voyageur”), a Canadian developer…
